Fractional Flow Reserve Market Size

Fractional Flow Reserve Market Analysis

The fractional flow reserve market is expected to register a CAGR of 13.2% during the forecast period.

The healthcare system had witnessed enormous challenges as a result of the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to reduce the risk of viral transmission, as most chronic therapies were regarded as non-urgent. It was observed that cardiovascular care delivery during the COVID-19 pandemic period was significantly reduced due to the lag in elective diagnostic testing and face-to-face patient care, as per the article published by the Radiology Cardiothoracic Imaging Society in August 2020. The fractional flow reserve (FFR) measures the ratio of the maximal myocardial blood flow in the presence of a stenosis, helping interventional cardiologists to determine the appropriate use of angioplasty and stenting. Thus, the reduction in cardiovascular services and procedures during the COVID-19 pandemic significantly affected the market's growth. However, cardiovascular patients were recommended to maintain their FFR therapy in order to improve their chances of survival and better control their immune system's capacity to resist the SARS-CoV-2 virus. Such instances bolstered the growth of the market amid the pandemic and are expected to continue the same trend over the next few years, as per the analysis.

The major factors contributing to the market's growth include the higher prevalence of cardiovascular diseases and technological advancements in FFR products.

The wide prevalence of heart diseases in the world is expected to propel the growth of the market over the forecast period. In the year 2020-21, over 14,849 people in the United Kingdom were admitted to hospitals due to heart and circulatory diseases, as per the data published by the British Heart Foundation in February 2022. Likewise, according to the CDC's article titled "Heart Disease Facts" updated in February 2022, heart disease is one of the leading causes of death in the United States. The same source also reports that every year about 659,000 Americans have a heart attack. Thus, the large prevalence of cardiovascular cases around the world creates the need for fractional flow reserves for the diagnosis of coronary artery pressure differences, in turn boosting the market growth. Furthermore, low- and middle-income countries are also witnessing an upsurge in the prevalence of cardiovascular diseases due to a lack of primary healthcare programs that offer early detection and treatment of cardiovascular disorders, according to the data published by the WHO in June 2021. Hence, the market demand for FFR products is likely to increase in these regions over the coming years.

Moreover, the increase in research on the improvisation of fractional flow reserve products is contributing to market growth. For instance, a group of researchers from the United Kingdom and Italy evaluated a clinical solution to improve the fractional flow reserve pullback for the assessment of stenosis in the event of serial disease, as per the data published by the Journal of Invasive Cardiology in July 2021. Such studies regarding the newer inventions related to fractional flow reserves are expected to significantly boost the market's growth over the forecast period.

However, the stringent regulatory framework for fractional flow reserve technologies is expected to slow down the growth of the studied market over the study period.